AzTrials
AzTrials

Hearing LossNCT03713554

Use of Functional Near-infrared Spectroscopy to Investigate Role of Human Auditory Cortex Plasticity and Multi-sensory Integration on Cochlear Implant Performance After Single-sided Deafness

An observational study of Hearing Loss, run by University of Michigan.

Withdrawn

Withdrawn. The study stopped before anyone enrolled.

Official record
Search all trials

Trial summary

The timing of brain changes that may influence hearing rehabilitation within human A1 after single-sided deafness (SSD) is not known. The goal is to determine when A1 neural plasticity occurs following SSD onset. Read more about this study

Who is it for?
Ages 18 to 120 yearsHealthy volunteers can take part
Conditions the study is for
Hearing Loss
What is being tested?
FNIRS Observational
Type of treatment
Surgery or procedure
How many people
0 participants
Where
No sites listed yet
Study dates
May 2025to 1 Oct 2025
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 120 years
  • All sexes
  • Healthy volunteers accepted
  • Adult, Older adult

Study population: SSD Patients

Who may be able to join

  • Adults over age 18

Who cannot join

  • prior otologic surgery
  • any SSD less than profound hearing loss
  • any subjected treated at an outside institution

About this study

The timing of brain changes that may influence hearing rehabilitation within human A1 after single-sided deafness (SSD) is not known. The goal is to determine when A1 neural plasticity occurs following SSD onset.

Read the detailed description

Sudden onset, profound unilateral sensorineural hearing loss, or single-sided deafness (SSD) is common (60,000 annually in US). Permanent SSD leads to listener disability and long-term challenges with sound localization and speech perception. The only definitive auditory rehabilitation for SSD is a cochlear implant (CI). Limited research on optimal timing for CI after SSD exists since insurance authorization typically requires bilateral deafness for CI placement. Secondly, limited CI compatible brain imaging technology exists to investigate changes pre- and post-CI in SSD. Thus, lack of systematic research results in random CI placement in SSD with inconsistent auditory performance that may be due, in part, to variable neural activation in primary auditory cortex (A1). Animal models and humans with SSD show enhanced A1 neural responses with sound stimulation of the remaining only-hearing ear1,2. Also, cross-modal plasticity3 (increased A1 neural responses to non-auditory sensory systems) leads to preferential A1 activation to somatosensory and visual stimuli4,5,6 in SSD. Essentially, non-auditory sensory systems "recruit" A1 neurons away to become responsive to new non-auditory stimulation. This limits the ability of A1 neurons to respond to auditory stimulation once CI rehabilitation is implemented. Importantly, a sensitive time window after SSD when these brain changes occur may impact A1 neural auditory responses and ultimately CI performance and speech perception.

Activation strength of A1 neurons is associated with optimal CI speech recognition and performance7,8. The investigators predict that if A1 neurons opposite SSD are kept active by increased sensitivity to only-hearing ear stimulation after SSD they would be less likely to be "reassigned" to non-auditory cross-modal plasticity. Alternatively, if only-hearing ear inputs to A1 are not sufficient, or if more somatosensory and/or visual inputs occur after SSD, fewer A1 neurons will be available to respond to CI stimulation and speech performance may suffer. The objective of these studies is first, to understand the timing and nature of both A1 cross-modal plasticity (sensitivity to somatosensory and/or visual systems) and only-hearing ear pathway enhancement in SSD. Second, is to examine the impact of CI on reversing these changes that may affect CI performance.

Human research on SSD and CI is sparse due to inadequate brain imaging technology that can measure A1 neural activity that is also CI compatible. Functional near-infrared spectroscopy (fNIRS) and event-related potentials (ERPs) with electroencephalography (EEG), when used together, can capture localization (fNIRS) and timing (EEG) of correlates of A1 neural responses (fNIRS) to distinguish between the effects of cross-modal and only-hearing ear stimulation pre- and post-CI. Using stimulation/silence block recording conditions in SSD adults, A1 hemodynamic responses (correlates of neural activity) and resting state functional cortical connectivity (RSFC; index of inter-cortical connections) will be measured with fNIRS and ERPs and correlated with only-hearing ear and cross-modal plasticity9,10 and CI speech performance11.

Specific Aim 1: Determine when A1 neural plasticity occurs following SSD onset. The timing of brain changes that may influence hearing rehabilitation within human A1 after SSD is not known. The goal of this aim is to identify plasticity that occurs when there is no CI intervention and characterize when A1 neurons are either influenced by only-hearing ear, somatosensory and/or visual inputs after SSD. Experiment 1. A1 hemodynamic responses (fNIRS correlate of neural activity) and changes in brain RSFC and ERPs to somatosensory, visual and only-hearing ear stimulation will be recorded 1, 3, 6, 9 and 12 months after SSD onset. The investigators predict cross-modal plasticity and A1 responses to only-hearing ear stimulation after SSD will have specific timing patterns of onset.

Specific Aim 2: Identify changes in A1 neural plasticity that follows CI rehabilitation.

The goal of this aim is to determine how and when CI placement affects A1 plasticity in SSD. As such, the investigators will determine when and if brain changes can be prevented that may hinder eventual CI performance. Experiment 2: Participants following CI placement that is either early- (<6mos), delayed- (6-12mos) or late- (>12mos-5yrs) after SSD and random insurance authorization will be analyzed for hemodynamic responses, changes in RSFC and ERPs to somatosensory, visual, CI, and only-hearing ear stimulation 1-12 months after CI. The investigators predict optimal CI speech performance will be associated with stronger fNIRS/ERP responses to early- and mid-CI placement that will reverse A1 responses to cross-modal stimulation.

Specific Aim 3: Identify neurocognitive profiles of successful CI rehabilitation of SSD. A1 plasticity pre- and post-CI and its relationship to speech performance in SSD will be measured. Experiment 3: CI speech performance testing will be conducted and results are expected to correlate with degrees/timing of plasticity from Aims 1 and 2. The investigators predict those with less A1 cross-modal plasticity and greater responses to the only-hearing ear will show better CI speech performance, while greater A1 responses to somatosensory and/or visual stimulation will perform more poorly with CI.

Clinical Significance: The investigators predict that this project will uncover timing and mechanisms of key auditory brain plasticity that follows adult-onset SSD and CI rehabilitation. This work will also demonstrate that fNIRS may prove to be a superior measure of A1 plasticity that could be used going forward to improve the timing of placement of CI for SSD to optimize speech performance and auditory rehabilitation.

Conditions
Hearing Loss
Being tested
FNIRS Observational
Keywords
SSD, unilateral hearing loss
Medical subject headings
Hearing Loss, Hearing Loss, Unilateral

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • FNIRS ObservationalProcedure or surgery

    In addition to completing an Informed Consent and survey questions, fNIRS Imaging and Electroencephalography (EEG) will take place will take place:The fNIRS imaging is experimental technology that has not been approved by the FDA. EEG is a noninvasive way to record electrical activity of the brain. The recording device is made up of electrodes that are fixed to a snug-fitting elastic cap. An MRI and EEG will follow the fNIRS procedure. The MRI will be performed before participants undergo fNIRS or EEG. The MRI will be done to show there are no lesions in the inner ear and therefore is a recruitment clearance tool.

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Change in Hemodynamic activity (fNIRS correlate of neural activity) in primary auditory cortex (A1) other non-auditory (somatosensory and visual) after single sided deafness; before and after cochlear implantation (CI).

    Functional near-infrared spectroscopy (fNIRS) is a non-invasive tool for measuring cortical hemodynamic activity in human auditory and non-auditory studies. fNIRS measures changing optical properties of the brain using infrared (IR) light to extrapolate and quantify hemodynamic responses through neurovascular coupling. When a specific brain region is activated, fNIRS measures changes in local hemoglobin as an index/correlate of neural activity within a chosen brain region.

    Measured: 12 months

Secondary outcomes (3)
  1. Resting state functional connectivity (RSFC; connectivity) between primary auditory cortex (A1) and other non-auditory (somatosensory and visual) cortices after single sided deafness; before and after cochlear implantation (CI).

    Resting state functional connectivity (RSFC) is the association of baseline activity between two brain regions. Although RSFC portends anatomical/structural interactions it does not assess activity at the individual neuron level. By assessing RSFC, we obtain information regarding spatiotemporal patterns of hemodynamic cortical responses across brain regions, which are thought to reflect plastic changes that play a role in both adaptive and maladaptive conditions. RSFC has been proposed to represent contextual influences of connections involved in local processing, connections between regions that are likely to work together in the future, or serve to coordinate neural activity.

    Measured: All fNIRS recordings will be taken at baseline (Aim 1) 1,3,6,9 and 12 months after single-sided deafness and at the same intervals after CI (Aim 2).

  2. Event-related potentials (ERPs from EEG recordings) in auditory cortex (A1) and other non-auditory (somatosensory and visual) cortices after single sided deafness; before and after cochlear implantation (CI)

    Electroencephalography (EEG) is another non-invasive method used to capture neuro-electric activity. Scalp electrodes measure currents that flow during excitation of cortical pyramidal neurons. EEG measures event-related potentials (ERPs) that are fluctuations time-locked to an event or stimulus onset. Many investigative approaches combine fNIRS for spatial resolution and EEG for temporal resolution as each is linked to the same neuronal activities and therefore complementary.

    Measured: All EEG recordings will be taken at baseline (Aim 1) 1,3,6,9 and 12 months after single-sided deafness and at the same intervals after CI (Aim 2).

  3. Cochlear implant (CI) speech performance

    All CI participants will undergo formal speech recognition testing per the clinical standard of care. Measures commonly used in clinical care of participants with CIs will be used in this study. Consonant-Nucleus-Consonant (CNC) monosyllabic words will be presented at a level of 60dB sound pressure level (SPL) in quiet. Additionally, two lists of sentences from the Bamford-Kowal-Bench Speech-in-Noise-Test (BKB-SIN) will be administered according to recommendations of the Minimal Speech Test Battery and will determine the SNR at which participants understand 50% of the words in the sentences.

    Measured: Cochlear implant speech performance will be measured 6 and 12 months after implantation (Aim 3).

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted19 Oct 2018
  2. Study startMay 2025 (estimated)
  3. Primary completionOct 2025 (estimated)
  4. Study completion1 Oct 2025 (estimated)

Why it stopped: Anticipated funding was never acquired to begin actual enrollment.

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Other
Time perspective
Prospective
Enrolment
0 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT03713554
Sponsor's protocol ID
HUM00137093
Status last verified
Jun 2025
First submitted
10 Oct 2018
Last updated
26 Jun 2025
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Yes: The researcher is open to sharing data by an appropriate mechanism indicated by NIH program staff.

Questions about this trial

What is this clinical trial studying?

An observational study of Hearing Loss, run by University of Michigan.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 1 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: withdrawn, as of the sponsor's last update on 26 Jun 2025. Status can change between updates, so confirm with the study contact before making plans.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study was withdrawn before enrolling participants, so there are no results.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Change in Hemodynamic activity (fNIRS correlate of neural activity) in primary auditory cortex (A1) other non-auditory (somatosensory and visual) after single sided deafness; before and after cochlear implantation (CI). (time frame: 12 months). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 26 Jun 2025.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in